Nanoform

Activities: Drug Delivery Research & Development

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. Nanoform’s capabilities include GMP manufacturing and span the small to large molecule development space. The company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications.

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human...
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Research & Development

Nanoform and Takeda team up to advance plasma-derived therapy development

The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
Research & Development

Apalutamide study demonstrates the advantages of nanoforming for cancer treatment

Nanoform’s technology delivers some of the world’s smallest nanoparticles at clinical and commercial scale
Research & Development

Nanoform announces clinical results for Enzalutamide cancer drug

The nanotechnology expert has announced promising clinical results for its Enzalutamide drug to treat prostate cancer
Research & Development

Nanoform commenced relative bioavailability study of nanotechnology enhanced enzalutamide

Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilising Nanoform’s platform technologies
Ingredients

Nanoform grants Global STARMAP AI License to AstraZeneca

Nanoform Finland, an innovative nanoparticle medicine-enabling company has announced that it has granted AstraZeneca Plc a global online STARMAP licence
Drug Delivery

Nanoformed TargTex oncology drug candidate TTX101 receives FDA Orphan Drug Designation

Nanoform Finland Plc (Nasdaq Helsinki NANOFH; Nasdaq Stockholm NANOFS), an innovative nanoparticle medicine enabling company, announced its customer TargTex S.A. has been granted Orphan Drug Designation by the FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas
Drug Delivery

Nanoform and Celanese demonstrate enhanced drug delivery through the power of smaller implants

The API nanoparticles produced through Nanoform’s CESS technology and the Celanese VitalDose EVA copolymer delivery technology have the potential to enable enhanced sustained release
Subscribe now